Allergan Inc. has won a ruling in federal court that its patents on Alphagan, which lowers pressure in the eye in patients with open-angle glaucoma and ocular hypertension, were infringed.
TEL AVIV (MarketWatch) -- Allergan Inc. won a ruling in federal court that its patents on Alphagan, which lowers pressure in the eye in patients with open-angle glaucoma and ocular hypertension, were infringed.
The ruling came in US District Court in Wilmington, Del., in Allergan's patent-infringement suit against Exela of India and Apotex of Canada, Allergan said in a statement late on Friday.
The court ruled that five patents asserted by Allergan against the defendants' proposed generic versions of the drug were valid and enforceable, the Irvine, Calif., producer of pharmaceuticals and medical devices focused on eye care said.
With the ruling, the US Food and Drug Administration must delay clearance of the defendants' proposed generic versions of Alphagan, generically brimonidine, until the last of the patents expire, in 2022, Allergan said.
AAO 2024: Detail outlined for Artificial Intelligence Innovation Center at Wilmer Eye Institute
October 24th 2024During a conversation at the American Academy of Ophthalmology annual meeting in Chicago, T.Y. Alvin Liu, MD, discussed plans for the James P. Gills Jr, MD, & Heather Gills Artificial Intelligence Innovation Center at the Wilmer Eye Institute at Johns Hopkins Medicine.
AAO 2024: Transient vision loss with Alexander Fein, MD
October 21st 2024Alexander Fein, MD, spoke with the Eye Care Network to share how to approach a patient presenting with transient vision loss, what this type of vision loss can mean, and what additional testing might be needed to determine the best plan for care.